- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Inqovi Tablets, FDA Approved for Treatment of MDS and CMML, Available at Biologics by McKesson
Inqovi was approved by the FDA on July 7, 2020, for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).
CARY, N.C., Aug. 24, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for Inqovi (decitabine and cedazuridine) tablets for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), 2 blood malignancies.
Inqovi, approved by the FDA on July 7, 2020, is a fixed-dose oral C-DEC (combination of decitabine and cedazuridine). The FDA granted this therapy orphan drug designation and approved Inqovi through its Priority Review process. By inhibiting cytidine deaminase in the gut and the liver, Inqovi enables the DNA hypomethylating agent, decitabine, to be taken orally for five days to reach systemic exposure levels that match those from five days’ worth of intravenous administration.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
